Maryland Heights, MO, February 02, 2017 --(PR.com
)-- The global companion diagnostics market to reach nearly USD 4.5 Billion in 2020, at a CAGR of 10% from 2016 to 2020, due to higher demand for in vitro diagnostics and targeted therapeutics.
Browse Companion Diagnostics Market by Indication or Disease Type (Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer, Melanoma) 2016-2020 report at https://www.ihealthcareanalyst.com/report/companion-diagnostics-market/
The emergence of targeted therapies in oncology brings an increased need for companion diagnostic tests. Companion diagnostics are medical devices that help physicians to decide the treatments and effective dosage for patients and which are tailored specifically to the patient. It is an in vitro device, which provides information that is essential for the safe and effective use of a corresponding drug or biological product. Companion diagnostics (CDx) are the molecular tests or assays intended to assist physicians in making effective treatment decisions based on the patient response to the ongoing treatment with targeted therapeutic medicines. These diagnostic tests ensure the commercialization of safer and efficient targeted therapeutics with minimal or no side effects, while ensuring economic benefits to the patients.
The global companion diagnostics market report estimates the market size (Revenue USD million - 2013 to 2020) for market segmentation based on indication or disease type (breast cancer, colorectal cancer, gastric cancer, lung cancer, melanoma, etc.), and forecasts growth trends (CAGR% - 2016 to 2020). The global companion diagnostics market research report is further segmented by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global companion diagnostics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global companion diagnostics market and included in this report are Abbott Laboratories, Agendia N.V., Agilent Technologies, Inc., BioGenex Laboratories, Inc., bioMérieux SA, GE Healthcare Ltd., Genomic Health, Inc., Qiagen N.V., Resonance Health Analysis Services Pty Ltd., Hoffmann-La Roche Ltd., Siemens Healthcare, and Thermo Fisher Scientific.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/companion-diagnostics-market/
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043